ResearcherMudanjiang Medical UniversityActive in the last 2 years

Lantao Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8025-7222; OpenAlex author ID A5075854198. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Research progress of pancreatic cancer based on ferroptosis-cuproptosis interaction (Review). Last author DOI 10.3892/ol.2026.15883 ↗
Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation. Co-author DOI 10.1186/s13046-025-03409-4 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wenqing Liu · 1 shared paper, 2026 · strength 0.33
- Paper Research progress of pancreatic cancer based on ferroptosis-cuproptosis interaction (Review). DOI 10.3892/ol.2026.15883 ↗
Pengyu Wang · 1 shared paper, 2025 · strength 0.20
- Paper Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochon… DOI 10.1186/s13046-025-03409-4 ↗
Yukuan Feng · 1 shared paper, 2025 · strength 0.20
- Paper Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochon… DOI 10.1186/s13046-025-03409-4 ↗
Jihui Hao · 1 shared paper, 2025 · strength 0.20
- Paper Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochon… DOI 10.1186/s13046-025-03409-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.